Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 6 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 3 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Low-energy diet helps maintain long-term weight loss in obese patients with knee osteoarthritis

18 Sep 2017
You are what you read: To report research findings on studies, in regards to diet and nutrition, accurately, would influence individuals’ choices about what to eat and drink.

The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.

Researchers randomized 153 participants (mean age 63.8 years; mean body mass index, 33.3 kg/m2; 83 percent women) to either the intermittent treatment (IN) group with LED for 5 weeks every 4 months for 3 years (n=76) or to daily meal replacement of one to two meals for 3 years (regular [RE] group; n=77). Attention by dietitians and the amount of formula products were similar.

The participants were recruited between June and December 2009 from the osteoarthritis outpatient clinic at Copenhagen University Hospital in Frederiksberg, Denmark. They had previously completed a 68-week lifestyle intervention trial and lost an average of 10.5 kg or 10 percent of their initial body weight.

Changes in body weight and proportion of participants receiving knee replacements were the primary endpoints, which were analysed on the intention-to-treat population using baseline-carried-forward imputation for missing data.

Of the participants, 53 in the IN group and 56 in the RE group completed the trial. Weight increased by 0.68 kg in the IN group and by 1.75 kg in the RE group (mean difference, ‒1.06 kg; 95 percent CI, ‒2.75 to 0.063; p=0.22). The rates of alloplasty were low and did not differ in both groups (IN group: eight of 76 participants; RE group: 12 of 77 participants; p=0.35).

“These results challenge the commonly held assumption that weight regain in the long term is inevitable,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 6 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
2 days ago
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 3 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.